Recode Health Ventures

Recode Health Ventures is a specialist venture capital firm dedicated to investing in healthcare AI companies. Based in San Francisco and London, the firm backs founders who believe that artificial intelligence and other emerging platforms have the potential to revolutionize healthcare, treating and curing diseases that impact billions of lives worldwide. Their portfolio spans the United States and Europe, showcasing pioneering ventures at the forefront of medical innovation. From gene targeting and antibody development to cell therapy, cardiology, and surgical guidance, these companies are advancing medical science and reshaping the landscape of healthcare delivery. Recode prefers to invest early and to back founders with strong technical backgrounds. In November 2024, Recode Ventures, in partnership with Eli Lilly and Company, launched Recode Edge, a multi-million dollar investment program for early-stage AI-first healthcare startups. This program offers pre-seed financing to select founders, focusing on innovators using AI in the life sciences. The most promising companies receive equity investment to support their growth and impact. The program aims to foster innovation by identifying the most promising AI-first solutions in healthcare and providing them with the resources needed to develop disruptive products. The top teams selected benefit from tailored mentorship, strategic partnerships, and funding opportunities. Recode Ventures' mission is to empower the brightest minds from around the world to push the boundaries of what's possible in healthcare, providing them with the resources and support needed to bring groundbreaking ideas to life. Their focus on early-stage investments and backing founders with strong technical backgrounds underscores their commitment to advancing healthcare through innovative technologies.